Cargando…
Effects of glucagon‐like peptide‐1 analogue treatment in genetic obesity: A case series
Obesity is highly prevalent and comes with serious health burden. In a minority, a genetic cause is present which often results in therapy‐resistant obesity. Liraglutide is a glucagon‐like peptide‐1 (GLP‐1) analogue, which has beneficial effects on satiety and weight in common obesity. We present th...
Autores principales: | Welling, Mila S., de Groot, Cornelis J., Kleinendorst, Lotte, van der Voorn, Bibian, Burgerhart, Jan Steven, van der Valk, Eline S., van Haelst, Mieke M., van den Akker, Erica L. T., van Rossum, Elisabeth F. C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9286843/ https://www.ncbi.nlm.nih.gov/pubmed/34291582 http://dx.doi.org/10.1111/cob.12481 |
Ejemplares similares
-
Effects of Glucagon-Like-Peptide-1 Analogue Treatment in Genetic Obesity
por: Welling, Mila Sofie, et al.
Publicado: (2021) -
The Narrative of a Patient with Leptin Receptor Deficiency: Personalized Medicine for a Rare Genetic Obesity Disorder
por: Welling, Mila S., et al.
Publicado: (2023) -
Impact of the COVID-19 Pandemic and Related Lockdown Measures on Lifestyle Behaviors and Well-Being in Children and Adolescents with Severe Obesity
por: Welling, Mila S., et al.
Publicado: (2021) -
Resting Energy Expenditure and Body Composition in Children and Adolescents With Genetic, Hypothalamic, Medication-Induced or Multifactorial Severe Obesity
por: Abawi, Ozair, et al.
Publicado: (2022) -
RF02 | PSAT110 Resting Energy Expenditure and Body Composition in Children and Adolescents with Genetic, Hypothalamic, Medication-Induced or Multifactorial Severe Obesity
por: Abawi, Ozair, et al.
Publicado: (2022)